Cullen/Frost Bankers, Inc. Alkermes Plc. Transaction History
Cullen/Frost Bankers, Inc.
- $7.23 Billion
- Q3 2024
A detailed history of Cullen/Frost Bankers, Inc. transactions in Alkermes Plc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 192 shares of ALKS stock, worth $5,520. This represents 0.0% of its overall portfolio holdings.
Number of Shares
192
Previous 161
19.25%
Holding current value
$5,520
Previous $3,000
66.67%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ALKS
# of Institutions
363Shares Held
181MCall Options Held
175KPut Options Held
96.6K-
Black Rock Inc. New York, NY29.1MShares$837 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$545 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD13MShares$374 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA12.7MShares$364 Million0.06% of portfolio
-
State Street Corp Boston, MA9.19MShares$264 Million0.01% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.72B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...